Podcasts about diabetes technology

With a number of late-breaking presentations and high-profile phase 2 and 3 trials, the 2025 American Diabetes Association (ADA) Scientific Sessions reflect how rapidly the treatment landscape for obesity and diabetes is evolving. This year's meeting, held June 20–24 in Chicago, will showcase significant updates on combination therapies, once-weekly insulin regimens, and novel mechanisms that may redefine standards of care for both type 1 and type 2 diabetes. Among the highlights: new efficacy and safety data for GLP-1–based therapies, novel amylin analog combinations, and once-monthly treatment options signal a shift toward personalization and convenience in metabolic care. In this special episode of Diabetes Dialogue cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, preview the most anticipated data, explore clinical implications, and discuss what may come next in the exciting pipelines for diabetes and obesity. During the meeting, Isaacs will also participate in a debate on over-the-counter continuous glucose Monitoring with David Ahn, MD, of Hoag, on Friday, June 20, and Bellini will chair 2 sessions, “Real-World Automated Insulin Delivery System Results” on June 20, and “Advances and Trends in Diabetes Technology” on June 22.

In this episode of Diabetes Dialogue, cohostsDiana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, examine a newly released American Diabetes Association (ADA) consensus report titled Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention. The publication emphasizes the importance of recognizing MASLD as a critical comorbidity in individuals with type 2 diabetes and prediabetes and outlines guidance for clinicians to improve early detection, risk stratification, and treatment strategies. The episode begins by placing MASLD in historical context alongside other comorbidities such as cardiovascular disease, chronic kidney disease, and hypertension. The hosts explain that MASLD, previously referred to as nonalcoholic fatty liver disease or NAFLD, reflects a metabolic-driven pathology and is now better understood as a progressive condition that increases the risk of cirrhosis, liver transplantation, cardiovascular disease, and impaired quality of life. The more advanced form, MASH (Metabolic dysfunction-associated steatohepatitis), represents progression toward hepatic fibrosis and cirrhosis. A major focus is the Fibrosis-4 (FIB-4) score, a noninvasive, cost-effective screening tool calculated from common laboratory tests (platelets and liver function markers) to assess fibrosis risk. The consensus report advises routine FIB-4 scoring in adults with type 2 diabetes, particularly those with central obesity. Based on risk thresholds, further evaluation may involve transient elastography (FibroScan), advanced imaging, or hepatology referral. The hosts commend the ADA for offering a clear clinical algorithm for evaluation and referral, as well as pharmacotherapy recommendations tailored to disease severity. For individuals with early-stage fibrosis, lifestyle modification and diabetes therapies such as GLP-1 receptor agonists (eg, semaglutide) are first-line approaches. For advanced fibrosis (F2–F3), resmetirom is the only currently approved treatment for MASH. The report also highlights complications from hepatic dysfunction—including impaired hypoglycemia awareness and sarcopenia—underscoring the broader metabolic impact of MASLD. Isaacs and Bellini stress that MASLD should be approached with the same clinical rigor as other diabetes-related complications. They recommend integrating automated FIB-4 scoring in EHRs, interdisciplinary collaboration with hepatology, and clinician education using decision tools from the consensus report. Reference: Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. Published online May 28, 2025. doi:10.2337/dci24-0094

In this episode of Diabetes Dialogue, co-hosts hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss significant developments in diabetes care from May 2025, including Medtronic's restructured business model, Sequel Twiist's technological collaboration with Abbott, and Breakthrough T1D's efforts to advance early detection of type 1 diabetes (T1D) through national screening initiatives. The discussion opens with news of Medtronic's decision to spin off its diabetes division into a standalone entity, currently referred to as “New Diabetes Company.” While the final name is forthcoming, the move is intended to streamline operations and accelerate innovation within the diabetes space. The hosts highlight the company's promising technology pipeline, including the forthcoming 800 series insulin pump with full smartphone control and plans for a tubeless insulin delivery system. Both experts express optimism that the independence may foster greater agility in product development, enhance accessibility, and maintain a focus on user-centered design, including for populations with visual impairments. Next, Isaacs and Bellini examine the announcement of the Sequel Twiist partnership with Abbott to integrate continuous ketone monitoring (CKM) into a hybrid sensor, which is expected to function similarly to the FreeStyle Libre 3. This device, still in development, will provide real-time data on both glucose and ketone levels—a critical advance for people with type 1 diabetes using insulin pumps, who are at elevated risk for diabetic ketoacidosis (DKA). While excited about the potential for earlier DKA detection, Bellini emphasizes the importance of cost-effective implementation and integration with existing pump platforms. The episode concludes with coverage of Breakthrough T1D's advocacy before the US Preventive Services Task Force to support routine screening for T1D autoantibodies. The goal is to identify individuals in early stages of the disease to prevent DKA and misdiagnosis. The hosts note that despite advancements in understanding T1D progression, many patients remain undiagnosed until presenting with DKA or are mistakenly classified as having type 2 diabetes. References: Medtronic plc. Medtronic announces intent to separate Diabetes business. Medtronic News. Published May 21, 2025. Accessed June 2, 2025. https://news.medtronic.com/2025-05-21-Medtronic-announces-intent-to-separate-Diabetes-business Sequel Med Tech. Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott's Future Dual Glucose-Ketone Sensor. GlobeNewswire News Room. Published May 22, 2025. Accessed June 2, 2025. https://www.globenewswire.com/news-release/2025/05/22/3086535/0/en/Sequel-Med-Tech-to-Integrate-twiist-Automated-Insulin-Delivery-AID-System-with-Abbott-s-Future-Dual-Glucose-Ketone-Sensor.html Breakthrough T1D. Breakthrough T1D Submits Application to Make Screening for Type 1 Diabetes Part of Recommended Preventive Services in the US - Breakthrough T1D. Breakthrough T1D. Published May 21, 2025. Accessed June 2, 2025. https://www.breakthrought1d.org/for-the-media/press-releases/breakthrough-t1d-submits-application-to-make-screening-for-type-1-diabetes-part-of-recommended-preventive-services-in-the-us/

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, are joined by Roy Beck, MD, PhD, executive director of the Jaeb Center for Health Research, to discuss the INHALE-3 trial, an adult study evaluating technosphere inhaled insulin (Afrezza) in comparison to standard diabetes therapies, including automated insulin delivery (AID) systems. Beck outlined his center's transition from ophthalmology-focused research to becoming a key player in diabetes trials over the last 25 years, particularly in technology-driven therapies. The conversation explores inhaled insulin's pharmacokinetic profile—its rapid onset and short duration, which more closely mimics physiologic insulin responses than injected rapid-acting analogs. The INHALE-3 trial randomized adults with type 1 diabetes (T1D), including nearly 50% who were on AID systems, to either continue their current regimen or switch to once-daily insulin degludec plus Afrezza for meals and corrections. Surprisingly, Beck highlighted participants willing to suspend AID use to try the inhaled approach, allowing for a head-to-head comparison. The study met its primary non-inferiority endpoint for HbA1c, with outcomes from Afrezza plus basal insulin comparable to those achieved with AID and multiple daily injections. However, Beck emphasized the heterogeneity in response. Approximately 30% of participants switching to Afrezza achieved notably better glycemic control (including greater reductions in HbA1c and less time >250 mg/dL), while a similar proportion performed worse, largely depending on their engagement and dosing frequency. CGM use was required in the study, enabling patients to re-dose Afrezza postprandially as needed, a key factor in those who succeeded. Beck also indicated that overnight glycemic control remained a challenge. While Afrezza performed well during daytime periods, AID systems outperformed it overnight—an expected finding given AID's strength in basal modulation. Weight gain was also lower in the Afrezza group, offering an additional potential advantage. Hosts discussed real-world use cases combining AID with Afrezza, with Beck sharing his son's personal success using Afrezza alongside Tandem Diabetes' Control-IQ in sleep mode, a workaround to prevent algorithmic overlap. He noted future integration could be more seamless with upcoming Bluetooth-enabled Afrezza inhalers or AID systems capable of receiving inhalation data. Safety data showed bronchospasm was rare in the trial, with no confirmed cases attributable to Afrezza. Cough was the most common side effect, generally mild and transient, while active asthma and smoking remained contraindications. Isaacs and Bellini highlighted Afrezza's potential as an underutilized but powerful option in the diabetes toolkit, particularly for patients seeking alternatives to injections or pumps, or looking for greater control over postprandial excursions. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Chapters 00:00:01 Introduction and Background of Dr. Roy Beck 00:02:16 Overview of Inhaled Insulin 00:06:31 INHALE-1 Pediatric Study 00:07:21 INHALE-3 Adult Study 00:11:18 Study Results and Participant Outcomes 00:19:57 Challenges and Future Directions 00:26:44 Side Effects and Safety Concerns 00:31:09 Conclusion and Final Thoughts

If you've ever googled a specific insulin pump or CGM, you may well have come across Nerdabetic's content online. His insightful but fun YouTube videos break down the latest and greatest in diabetes technology, helping people with diabetes to understand how they could benefit.In this episode I'm chatting to Kamil Armacky - the real Nerdabetic. We discuss his personal journey into technology after he was diagnosed with type 1 diabetes in 2012, how he went from his first Facebook post to meeting royalty in the name of type 1 diabetes, and how his content - and the impact his content having - has evolved since he started posting eight years ago.Offering personal stories as well as practical tips for the tech-curious, Kamil reveals his top tips for figuring out what insulin pump might work for you, what the diabetes CEOs really think, why the time in happiness is just as important as time in range - and how he ended up serving undercooked chicken on Junior Masterchef...CONNECT WITH KAMILFollow Nerdabetic on Instagram.Subscribe to his YouTube channel.Follow Nerdabetic on X.JOIN THE TYPE 1 ON 1 INSTAGRAM COMMUNITYCome and say hi @studiotype1on1 on Instagram. SPONSOR MESSAGE This episode of Type 1 on 1 is sponsored by Insulet, the makers of Omnipod tube-free insulin pump therapy. Using Omnipod 5 Automated Insulin Delivery has improved my diabetes management significantly with less diabetes decisions, and of course no multiple daily injections.  How? Well, Omnipod 5 automatically adjusts insulin every five minutes to help keep me in range, allowing life outside of type 1 diabetes to get bigger. If you want to know more, head to Omnipod.com.

Video Version Only on HCPLive! In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sit down with Steven Russell, MD, PhD, Chief Medical Officer at Beta Bionics, to discuss the latest real-world outcomes from the iLet Bionic Pancreas—an autonomous insulin delivery (AID) system cleared by the US Food and Drug Administration (FDA) in 2023. Russell outlines the iLet's fully automated design, which sets it apart from conventional AID systems by requiring no manual settings, carb ratios, or correction factors. The system determines 100% of insulin dosing, adapting continuously to glycemic trends without relying on user engagement. This autonomy makes the iLet particularly effective for individuals with suboptimal diabetes self-management or limited access to endocrinology care. New real-world data, covering 3,300 users from the first year of commercial rollout, reveal a mean baseline A1c of 8.5%—higher than the 7.8% in the pivotal trial and reflective of the broader U.S. type 1 diabetes (T1D) population. The iLet reduced glucose management indicator to 7.3%, yielding an average A1c reduction of 1.2%, more than double that seen in the pivotal study. Outcomes were most pronounced among those with severe hyperglycemia: users starting with A1c >14% saw average reductions of 7%, with low rates of diabetic ketoacidosis (DKA) and minimal increases in hypoglycemia (median time

This week on The Huddle, we're resharing an episode from last summer featuring Kristine Batty, PHD, APRN, BC-ADM, CDCES, FADCES as she discusses her experience both living with Type 1 diabetes and working with people with diabetes as a certified diabetes care and education specialist. She shares the importance of putting yourself in your client's shoes in order to understand their goals and pain points and support their needs, especially when it comes to diabetes technology.Visit danatech here: danatech l Diabetes Technology Education for Healthcare ProfessionalsLearn more about the latest developments in T1D screening here: T1D ScreeningView Kristine's video series below:https://www.youtube.com/watch?v=HPqraDx-aQwhttps://www.youtube.com/watch?v=SBYpv3LuzBwhttps://www.youtube.com/watch?v=otRUIrx6FkIhttps://www.youtube.com/watch?v=uDrDSSK99-A Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Video Version Only on HCPLive! Key Episode Timestamps 00:00:05 Introduction and Background of Luna Diabetes 00:02:27 Overview of Luna and Its Unique Features 00:04:58 Details of Luna's Functionality and User Experience 00:14:24 Clinical Trials and Feasibility Study Results 00:20:49 Potential Applications and Future Directions 00:24:54 Conclusion and Final Thoughts In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sit down with John Sjölund and Jon Brilliant, co-founders of Luna Diabetes, to explore their novel approach to automated insulin delivery (AID) designed specifically for individuals with diabetes using insulin pens. The discussion introduces Luna, a small, wearable overnight patch pump that delivers automated insulin microdoses during sleep, addressing one of the most persistent gaps in diabetes care: nighttime glucose variability. Unlike traditional AID systems that require full-day pump use, Luna is built for simplicity and intermittent use. It integrates with any continuous glucose monitor (CGM), requires no input on insulin type, and adapts automatically without user-programmed settings. The system supplements a patient's existing basal insulin, providing algorithm-driven microdoses of rapid-acting insulin at night. The device operates with minimal user interaction—patients fill the pod with up to 10 units of insulin, apply it before bed, and remove it in the morning. Preliminary data from Luna's feasibility study showed promising results: an average 10% increase in time-in-range and a 15% reduction in time spent above 250 mg/dL, without increased hypoglycemia. The ongoing pivotal trial, enrolling 120 participants with type 1 diabetes (T1D), aims to further evaluate safety, efficacy, and patient-reported outcomes, particularly sleep quality, across 13 weeks.  Sjölund and Brilliant emphasized Luna isn't designed to match the full clinical performance of traditional AID systems, but rather to expand access by lowering barriers—providing improved overnight control and reducing cognitive and emotional diabetes burden, especially for those who prefer to avoid pumps. Isaacs and Bellini highlighted Luna's potential not only for people with type 1 diabetes but also for those with type 2 diabetes (T2D), particularly in conjunction with GLP-1 therapies or for patients early in their insulin journey. Luna's no-training-required model could also enable broader adoption in primary care settings, where most diabetes management occurs. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! Full results from the SURMOUNT-5 trial show tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide 2.4 mg (Wegovy) in adults with obesity, according to findings published in The New England Journal of Medicine and presented at the 32nd European Congress on Obesity. “The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management,” said principal investigator Louis J. Aronne, MD, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, in a press release. The phase 3b trial enrolled 751 participants across 32 US and Puerto Rican sites, with 750 receiving at least one dose of study drug. Participants were randomized to their maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). The primary endpoint was percent change in body weight at 72 weeks. Results showed tirzepatide produced a 20.2% average reduction in body weight versus 13.7% with semaglutide, a 6.5-point difference (P

Video Version Only on HCPLive!  In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new key updates on cotntinous glucose monitoring (CGM) systems for diabetes, incuding the Dexcom G7, Libre App, and Medtronic Simplera Sync. Dexcom G7 15 Day CGM On April 10, 2025, the FDA granted clearance to the Dexcom G7 15-day continuous glucose monitoring (CGM) system for individuals aged 18 years and older with diabetes. The G7 CGM now boasts the longest-lasting CGM system with 15.5 days of wear and best-in-class accuracy with a mean absolute relative difference (MARD) of 8.0%. Isaacs and Bellini discussed the sensor life of the G7 CGM, with Dexcom announcing only 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days. Abbott Libre App With the launch of the new Libre app, Abbott is replacing the Libre 2 and 3 apps with a new all-in-one app that works with all Libre sensors. With the upcoming discontinuation of Libre 2 and 3 (non-Plus) sensors in the US by September 2025, intermittent scanning will be phased out, improving data continuity and aligning with American Diabetes Association (ADA) recommendations. They also highlight Libre's new integration with Glooko, allowing direct data syncing via Bluetooth from the app. This streamlines clinical workflows, supports EHR integration, and includes features like voice-activated carb logging, reducing both patient and provider burden. Medtronic Simplera Sync On April 18, 2025, the FDA approved Medtronic's Simplera Sync sensor for use with its MiniMed 780G insulin delivery system, expanding CGM options for users. The new all-in-one, fingerstick-free sensor offers simplified insertion and enhanced user flexibility while maintaining compatibility with the system's Meal Detection™ technology and adaptive insulin algorithm. A limited US launch is planned for fall 2025. Isaacs and Bellini noted this long-awaited update could improve access and uptake in the US., especially for newly diagnosed patients, thanks to easier usability and compatibility with Medtronic's strong insulin delivery algorithm. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00:30 Dexcom G7 15-Day Sensor Approval 00:02:11 Challenges with Sensor Lifespan 00:06:00 Education and Replacement Process 00:09:27 Accuracy and FDA Approval Details 00:11:37 Libre's New Mobile App 00:16:55 Integration with Gluco 00:19:41 Medtronic's Simplera Sync Approval 00:23:03 Future Collaborations and Algorithms 00:28:05 Final Thoughts and Wrap-Up

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new Phase 3 data from the ESSENCE trial examining semaglutide 2.4 mg (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. With results published in The New England Journal of Medicine, hosts are joined by first author Arun J. Sanyal, MD, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, to discuss key takeaways from part 1 of the ESSENCE trial, semaglutide's impact on liver outcomes and weight loss, and what the data could mean for the future of MASH treatment. ESSENCE Once-weekly semaglutide 2.4 mg significantly improved liver outcomes in patients with metabolic dysfunction–associated steatohepatitis (MASH) and stage 2 or 3 fibrosis, according to findings from the ESSENCE trial. In part 1 of the ongoing, double-blind, placebo-controlled trial, 800 patients were evaluated at 72 weeks for two primary endpoints: resolution of steatohepatitis without worsening fibrosis, and fibrosis improvement without worsening steatohepatitis. Spanning 253 sites in 37 countries, the full trial enrolled 1197 biopsy-confirmed patients between May 2021 and April 2023. At the interim analysis, semaglutide achieved both primary endpoints. Resolution of steatohepatitis without fibrosis worsening occurred in 62.9% of patients receiving semaglutide compared with 34.3% in the placebo group (difference, 28.7%; 95% CI, 21.1–36.2; P

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss the newly published findings from the CATALYST trial, a prospective, observational study establishing the prevalence of hypercortisolism among individuals with difficult-to-control type 2 diabetes (T2D). CATALYST enrolled 1057 adults with T2D and suboptimal glycemic control (HbA1c, 7.5–11.5%) despite treatment with ≥2 glucose-lowering agents. All participants underwent a 1-mg overnight dexamethasone suppression test (DST), and common confounders were excluded. Hypercortisolism—defined as a post-DST cortisol level >1.8 µg/dL—was identified in 23.8% of participants, with even higher rates among those with cardiac disease (33.3%) or on ≥3 antihypertensives (36.6%). Adrenal imaging revealed abnormalities in about one-third of affected individuals. Isaacs and Bellini emphasized how striking it is that such a high proportion of patients met criteria for hypercortisolism, a condition historically considered rare. The trial challenges that perception, revealing that clinical features like persistent hyperglycemia and hypertension—despite optimized therapy—could reflect underlying endocrine dysfunction. They noted that neither A1c nor body mass index (BMI) alone predicted elevated cortisol, although medication intensity and comorbid conditions did. The conversation explored how the recognition of hypercortisolism could alter clinical management. Future studies will assess whether targeted treatments—such as cortisol-lowering pharmacotherapy, including mifepristone (Korlym), or adrenal surgery—can reduce medication burden, improve glycemic control, and lower cardiovascular risk. Isaacs and Bellini pointed out that many patients with hypercortisolism present without the classic phenotype, underscoring the importance of broader screening criteria. Looking ahead, they called for greater awareness among clinicians to consider screening in patients on intensive diabetes and blood pressure regimens who still fail to reach therapeutic goals. Identifying and treating hypercortisolism could open a new pathway to improving outcomes in this population. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00:01 Catalyst Trial Overview and Introduction 00:01:37 Patient Criteria and Initial Findings 00:04:18 Implications and Next Steps 00:05:23 Adrenal Imaging and Cardiac Disorders 00:07:22 Clinical Implications and Future Research 00:09:13 Demographic Differences and Future Directions

Registration is open now for ADCES25 taking place August 8-11 in Phoenix, AZ! Our conference planning chair Christina Whitehouse, RN, MSN, APRN, ARNP, FADCES, CDCES, shares what to look forward to at this year's conference, and why ADCES' annual conference is the place to be for all diabetes care and education specialists and other professionals in the diabetes space. Register for this year's annual conference at ADCES 2025 Annual MeetingExplore all there is to see in Phoenix at Roosevelt Row Arts District | Downtown Phoenix Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Video Version Only on HCPLive! In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss the top-line results from the ACHIEVE-1 trial evaluating orforglipron—an investigational, once-daily oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed by Eli Lilly—for adults with type 2 diabetes (T2D) inadequately controlled by diet and exercise. Isaacs and Bellini emphasized the clinical significance of orforglipron's Phase 3 data in the ACHIEVE-1 trial, which demonstrated substantial reductions in A1c (1.3–1.6%) from a baseline of 8.0% and notable weight loss averaging 16 pounds (7.9%) at the highest dose over 40 weeks. Impressively, more than 65% of participants achieved an A1c below 6.5%, meeting the American Diabetes Association (ADA)'s target for diabetes control. The hosts highlighted the convenience advantage of orforglipron compared to oral semaglutide, which has strict dosing requirements. Oral orforglipron can be taken without food or water restrictions, potentially increasing adherence and reducing treatment burden. They also noted the drug's favorable safety profile, with gastrointestinal side effects similar in type and incidence to existing GLP-1 RAs, and no hepatic safety signals observed in the trial. Beyond glycemic control, Isaacs and Bellini discussed the broader implications for obesity treatment, pointing to the drug's potential utility in weight management, pending regulatory submission. They explored the possibility of using injectable GLP-1 RAs for initial weight loss followed by oral maintenance with orforglipron—potentially lowering costs and improving access. The conversation touched on the upcoming ACHIEVE trial series, which will explore orforglipron in head-to-head comparisons with other agents, its use in insulin-treated T2D, and future indications including cardiovascular risk and kidney disease. While optimistic, the hosts stressed the need for cardiovascular outcomes data to confirm orforglipron's safety and potential benefits in this domain. If confirmed, they suggested orforglipron could become a cornerstone oral therapy for T2D and obesity. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00:01 Discussion on OR for GLP-1 Receptor Agonist 00:02:13 Potential Impact and Patient Preferences 00:03:59 Safety and Market Potential 00:05:13 Cost and Transition Options 00:06:32 Future Trials and Side Effects 00:08:55 Cardiovascular Outcome Data and Conclusion

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, are joined by Rifka Schulman-Rosenbaum, MD, director of inpatient diabetes at Long Island Jewish Medical Center and co-author of Establishing Screening Programs for Pre-symptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers, a new paper in the Journal of Clinical Endocrinology and Metabolism. With Bellini as a co-author of the piece, experts explored the increasing clinical and operational momentum behind screening for pre-symptomatic type 1 diabetes (T1D) and what it takes to implement effective programs in real-world settings. The conversation centers on the rationale and logistics behind identifying individuals in stages 1 and 2 of T1D—autoimmune stages characterized by multiple islet autoantibodies before clinical onset. With the availability of teplizumab (Tzield), a disease-modifying therapy shown to delay progression to stage 3 of T1D, the importance of early detection and standardized screening protocols has become more urgent. Schulman-Rosenbaum outlined how her work on the JDRF Breakthrough T1D initiative led to the development of actionable guidance aimed at frontline diabetes care providers. She highlights barriers to implementation—such as limited provider awareness of T1D staging and screening protocols—and details her institution's ongoing efforts to educate primary care clinicians and endocrinologists, including distributing screening handouts and creating streamlined workflows using dot phrases and dedicated follow-up slots. The discussion emphasizes targeted screening for high-risk groups, such as first- and second-degree relatives of individuals with T1D and patients with autoimmune diseases like Hashimoto's or celiac. Schulman-Rosenbaum emphasized the opportunity for endocrinologists to screen these patients directly during routine care and the utility of a centralized handout to guide test ordering and family engagement. Drawing from their paper, experts outlined practical steps for launching autoantibody screening programs: nominating a program champion, forming an implementation team, and embedding screening into existing clinical systems. Experts stressed the importance of using appropriate ICD-10 codes for insurance coverage and referenced a diagnostic coding table in their publication. Schulman-Rosenbaum also addressed the widespread issue of misdiagnosis, particularly in adults mistakenly classified as having type 2 diabetes, and outlines best practices for using antibody and C-peptide testing to refine diagnosis. She detailed her hospital's approach to inpatient screening, noting an increased use of autoantibody testing and follow-up coordination for patients with suspected T1D or latent autoimmune diabetes in adults (LADA). Finally, the episode highlighted how to monitor individuals who test positive for a single antibody or exhibit mild dysglycemia, noting that many fall outside established risk categories. Experts called for more research in this area and advocate for individualized monitoring strategies based on clinical risk, family history, and emerging glucose patterns—often using continuous glucose monitoring (CGM) data. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00:00 Introduction 00:02:18 Inspiration Behind the Paper 00:04:12 Challenges in Implementing T1D Screening 00:07:32 Educating Providers and Overcoming Barriers 00:09:32 Addressing Misdiagnosis of Diabetes 00:12:01 Inpatient Screening Practices 00:16:13 Support and Resources for Patients with Positive Antibodies 00:20:01 Conclusion and Final Thoughts

Video Version Only on HCPLive! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explored two key trial updates in type 2 diabetes (T2D) care at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions. SOUL Trial SOUL, a double-blind, placebo-controlled, event-driven trial, was designed to assess the cardiovascular effects of oral semaglutide (Rybelsus) in patients with T2D and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). A total of 9650 patients aged ≥50 years were enrolled across 450 centers in 44 countries. Analyses showed oral semaglutide (Rybelsus) was linked to a 14% reduction in major adverse cardiovascular events (MACE) in high-risk patients with T2D. This reduction included the incidence of cardiovascular (CV) death, myocardial infarction (MI), or stroke compared to placebo (HR, 0.86; 95% CI, 0.77 to 0.96; P = .006) over a median follow-up of 47.5 months. A 26% reduction in non-fatal MI was the primary driver of benefit, while safety findings identified gastrointestinal adverse events as more common with oral semaglutide. Based on these results, Novo Nordisk announced plans to pursue regulatory approval for a label expansion of oral semaglutide to include MACE risk reduction in adults with T2D and established CV disease. STRIDE Trial STRIDE, a double-blind, randomized, placebo-controlled trial initiated in 2020, assessed the effects of semaglutide 1.0 mg (Ozempic) on functional outcomes, including walking distance, in patients with T2D and peripheral artery disease (PAD). Conducted across 112 sites in 20 countries, the trial randomized 792 patients to receive semaglutide or placebo for 52 weeks. Analyses showed semaglutide use was associated with improvements in maximal walking distance, quality of life, and ankle-brachial index (ABI). SOUL met its primary endpoint, with semaglutide favoring the ratio from baseline in maximum walking distance at 52 weeks (1.21 [interquartile range, 0.95–1.55] vs 1.08 [0.86–1.36]), with an estimated treatment ratio (ETR) of 1.13 (95% CI, 1.06–1.21; P = .0004). At week 57, the improvement in walking distance was higher with semaglutide (ETR, 1.08; P = .038). Quality-of-life scores (VascuQoL-6) at week 52 were significantly higher in the semaglutide group (median difference, 1.00; P = .011), as were improvements in pain-free walking distance (ETR, 1.11; P = .0046). Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Editor's Note: In this episode, there was an error in the discussion about the new dosing for Rybelsus in the SOUL trial. The corrected information is that the 14 mg dose is now 9 mg with the new formulation, due to improved absorption. The full corrected statement is: “Instead of 3 mg, the new dose is 1.5 mg; instead of 7 mg, it's 4 mg; and instead of 14 mg, it's 9 mg.”

Video Version Only on HCPLive! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, reflect on major announcements and product updates from the Advanced Technologies & Treatments for Diabetes (ATTD) 2025 annual conference. The conversation opens with insights into Medtronic's new Simplera CGM, emphasizing its single-use, disposable design and fully disposable on-body form factor. The hosts highlight improvements over previous iterations, such as the absence of an inserter and a more streamlined adhesive system. Although accuracy data have yet to be released, Medtronic has initiated a pivotal trial, and expectations are high for competitive MARD performance. They then turn to Tandem Diabetes Care's Tandem Mobi pump, recently launched in the US market. The pump's compact size and phone control interface are praised for improving convenience and discretion. Bellini underscores how Mobi shifts the paradigm for pump wearability, with early feedback from patients indicating high satisfaction. Later, the hosts discuss Beta Bionics' insulin-only iLet Bionic Pancreas system, which has expanded availability in the U.S. They review recent clinical updates and ongoing efforts to integrate real-world user data. The system's unique algorithm, which doesn't require manual carb counting or standard pre-programming, continues to generate interest across clinical settings. Additional topics include anticipated innovation from Lilly's new pump platform, the competitive implications for CGM integration, and an emphasis on patient-centered device design. The episode closes with Isaacs and Bellini reflecting on the rapid evolution of diabetes technology and how practitioners can stay current with emerging tools and evidence-based practices. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Editor's Note: Control-IQ+ technology is cleared by the FDA for use in adults with type 2 diabetes in the United States, as of February 25, 2025. The podcast episode erroneously positioned the indication as forthcoming. On March 18, 2025, Tandem Diabetes Care announced the commercial launch, making Control-IQ+ available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes.

Video Version Only on HCPLive! In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center speak with Laurel Messer, PhD, RN, senior director of medical affairs at Tandem Diabetes Care, about the latest advancements in Control-IQ+, the company's next-generation automated insulin delivery (AID) technology. With clearance received from the US Food and Drug Administration (FDA) in February 2025, Tandem announced on March 18, 2025, that the Control-IQ+ hybrid closed-loop algorithm is now available for use in adults with type 2 diabetes (T2D) aged ≥18 years alongside people with type 1 diabetes (T1D) aged ≥2 years. Enhancements to the algorithm included a broader weight range (20–440 lbs) and insulin dosing parameters (5–200 units), representing a more inclusive algorithm. In this episode, Messer highlighted other new features in the updated algorithm, such as temp basal rate adjustments for exercise or illness and an extended bolus option of up to eight hours, which enhances flexibility in insulin management during meals. Messer also emphasized that Control-IQ+ offers a unique advantage: the ability to fine-tune correction factors, allowing providers to tailor insulin delivery for improved glycemic control. With the AutoBolus feature, Control-IQ+ predicts and corrects hyperglycemia every hour, significantly benefiting individuals who struggle with consistent mealtime bolusing. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Important Safety Information: RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older and for patients with type 2 diabetes, 18 years and older. BOXED WARNING: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds, as those are the required minimum values needed for Control-IQ+ to operate safely. Safety info: tandemdiabetes.com/safetyinfo.

In the first episode in a multi-part diabetes technology series, Kathryn Evans Kreider DNP, FNP-BC, BC-ADM, FAANP, joins The Huddle to discuss integrating diabetes technology into primary care. She talks about the importance of embracing digital technology in primary care and how health care professionals in primary care can take tangible steps to better utilize the technology available to them.Learn about the latest advances in diabetes technology on danatech:  Diabetes technology for healthcare professionals | DanatechCheck out the two-part Integrating Diabetes Technology into Primary Care course here: Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical ScenariosPart 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case Studies   Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

If I take Ozempic, Wegovy, Mounjaro, Zepbound, or any other GLP-1 weight loss drug, will I need to take it forever? What are the side effects of Ozempic? Do we know the long term effects of these weight loss drugs?Can Ozempic be prescribed for women in perimenopause or menopause? What can women do to create sustainable weight loss? How can we lose the weight and keep it off?Diana Isaacs, an endocrinology clinical pharmacy specialist answers the questions above and many others, as they pertain to the safety, sustainability and effectiveness of GLP-1 drugs. Diana serves as the Co-Director of Endocrine Disorders in Pregnancy and the Director of Education and Training in Diabetes Technology at the Cleveland Clinic Endocrinology and Metabolism Institute.From this educational conversation, I learned that certain GLP-1 medications can be used to lower blood pressure, help with cardiovascular disease, kidney disease, and sleep apnea!To be connected with Diana Isaacs, please email Vera Kessler, host of America's Top Rebbetzins at atrebbetzins@gmail.com

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss a pair of recently published studies examining the use of diabetes technology in adults with type 2 diabetes. SECURE-T2D A single-arm prospective study conducted at 21 US clinical centers, SECURE-T2D assessed the impact of automated insulin delivery (AID) on glycemic control in adults with type 2 diabetes using insulin for at least 3 months. The study enrolled 305 participants (mean age, 57 years; 57% female), with a diverse racial and ethnic representation, including 24% Black and 22% Hispanic or Latino. Following a 14-day standard therapy phase, participants used the Omnipod 5 AID system for 13 weeks. HbA1c decreased from 8.2% (SD, 1.3) at baseline to 7.4% (SD, 0.9) (mean difference, -0.8 percentage points; 95% CI, -1.0 to -0.7; P

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explore the updated American Diabetes (ADA) 2025 Standards of Care, focusing on therapeutic advancements in diabetes management. Hosts discussed the significant changes to treatment algorithms and new guidance designed to enhance outcomes for people with diabetes and related conditions. One of the major updates discussed is the expanded flexibility in the treatment algorithm for type 2 diabetes (T2D) and chronic kidney disease (CKD), including glucagon-like peptide-1 receptor agonists (GLP-1 RA), such as semaglutide, as an alternative to patients who may not tolerate sodium-glucose co-transporter 2 (SGLT2) inhibitors. Isaacs and Bellini emphasized the complementary benefits of combining these therapies, particularly for kidney protection and glucose management. The episode also highlighted updates on the use of GLP-1 RAs for patients with obesity-related heart failure with preserved ejection fraction (HFpEF), underscoring the evolving role of these medications beyond glucose lowering. The discussion then shifted to the introduction of recommendations for metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). GLP-1 RAs, dual GLP-1/GIP agonists, and combinations with pioglitazone are now recognized as promising treatment options to mitigate these risks. Hosts delved into the importance of identifying disease severity using FIB-4 scores and how these guidelines aim to address the rising prevalence of fatty liver disease among people with diabetes. Another noteworthy update focused on screening for type 1 diabetes (T1D), particularly in first-degree relatives of individuals with the disease. Isaacs and Bellini review the new staging framework, which classifies T1D progression into three distinct stages, and the inclusion of ICD-10 codes for accurate diagnosis. They also discussed the role of teplizumab (TZIELD) in delaying disease progression in individuals aged ≥8 years and what this could represent for early intervention. With practical insights and real-world applications, this episode provided a comprehensive look at how these updates from the ADA's 2025 Standards of Care will shape therapeutic decision-making and improve care for people with diabetes. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00 Updates to 2025 ADA Standards of Care 03:06 GLP-1 Agonists and SGLT2 Inhibitors Combination Therapy 04:34 Heart Failure Stratification and Obesity-Associated Heart Failure 07:04 Introduction of Liver Disease into Algorithms 10:28 Screening for Type 1 Diabetes and New Guidelines 13:57 Guidelines for Pre-Symptomatic Type 1 Diabetes 17:35 Nutrition and Medication Adjustments 20:45 Vitamin D Monitoring and Supplementation 22:12 ADA Standards of Care App

On our latest episode of The Huddle, Sheetal Shah, founder of MettaHealth Partners discusses the evolving realm of AI, the role DCESs and other health care professionals can play in embracing and adopting AI technology, and the importance of keeping a human element in the technology.Learn more about MettaHealth Partners here: MettaHealth PartnersLearn more about the National Institute of Standards and Technology (NIST) here: National Institute of Standards and TechnologyStay up to date on all things related to diabetes technology on danatech: Diabetes technology for healthcare professionals | Danatech Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sana announces beta cell transplantation without the need for immunosuppresion drugs, Modular Medical teams up with Nudge BG for a brand new completely closed-loop system, the FDA moves forward to crack down on compounded Ozempic and Mounjaro, Dexcom and Abbott bury the legal hatchett for a while, and more.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:     Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Big news from Sana Biotechnology. Their first in human study of islet cells without any immunosuppression appears to be a success. This is very early and hasn't yet been peer reviewed and published.. but after four weeks, there were no safety issues and the transplanted beta cells were producing insulin. Sana's CEO says  “As far as we are aware, this is the first study showing survival of an allogeneic transplant with no immunosuppression or immune-protective device in a fully immune competent individual. Safe cell transplantation without immunosuppression has the potential to transform the treatment of type 1 diabetes and a number of other diseases.”   I've reached out to Sana to get more on this.. love to talk to them soon.   https://www.bakersfield.com/ap/news/sana-biotechnology-announces-positive-clinical-results-from-type-1-diabetes-study-of-islet-cell/article_d0390fd6-99cb-53bd-b04d-9337121e01bf.html XX FDA says no for sotagliflozin as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).  Studies showed a meaningful reduction in A1C but a meaningful increase in DKA. The FDA first rejected this in 2019 and was resubmitted last summer. But The advisory committee voted 11 to 3 against the approval of sotagliflozin stating that the benefits of sotagliflozin do not outweight the risks in adults with T1D and CKD. Sotagliflozin is currently approved under the brand name Inpefa to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with 1) heart failure; or 2) type 2 diabetes mellitus, CKD, and other cardiovascular risk factors.  According to Lexicon, Inpefa will continue to be manufactured and made available to patients. https://www.renalandurologynews.com/news/fda-denies-approval-of-zynquista-for-type-1-diabetes-and-ckd/ XX Two companies we've been following are teaming up.. Modular Medical has an FDA clear patch pump and Nudge BG has an adaptive full closed loop. They've announced a new partnership agreement. From the release: Modular Medical's easy-to-use and cost-effective MODD1 insulin pump technology. Our combined system is intended to nudge blood glucose by making small changes to insulin delivery based on estimated glucose inputs from a continuous glucose monitor." Familiar name to some of you, Lane Desborough is the founder of Nudge BG. He says this will be a fully automated system, no mealtime bolusing needed.   https://www.accesswire.com/957703/modular-medical-announces-licensing-and-partnership-agreement-with-nudge-bg XX Beta Bionics filed for an initial public offering on Monday. The company did not disclose the number of shares it will offer or the price range. Beta Bionics plans for shares to be listed on the Nasdaq under the ticker symbol “BBNX.” The Irvine, California-based company makes an insulin pump called the iLet Bionic Pancreas, which was cleared by the Food and Drug Administration in 2023. Beta Bionics plans to use the proceeds to grow its sales and manufacturing infrastructure and develop new features for its device.   https://www.medtechdive.com/news/beta-bionics-insulin-pump-files-ipo/736805/     XX Tandem Diabetes Care, Inc. signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems.   There's a long history here – UVA is where the Control IQ algorithm was developed.  This agreement seems to keep the team together for another decade. https://www.businesswire.com/news/home/20250107162995/en/Tandem-Diabetes-Care-Enters-Multi-Year-Research-Collaboration-with-UVA-Center-for-Diabetes-Technology-for-Development-of-Advanced-Insulin-Delivery-Systems XX New study says insulin is still the best treatment for gestational diabetes, compared to oral glucose-lowering medications. Metformin and gluburide are being closely looked at since they're easier to administer, less costly, and have better acceptance among patients. But this study says insulin was a bit better – slight more babies were born larger for the metformin group, and more moms had hypoglycemia. https://www.medpagetoday.com/obgyn/pregnancy/113651 XX In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, the type 2 diabetes injection it sells as Victoza. Novo Nordisk last month filed a Citizen Petition with the FDA asking the federal agency to exclude its type 2 diabetes injection Victoza (liraglutide) from a proposed list of drugs eligible for compounding. https://www.biospace.com/fda/novo-launches-citizen-petition-to-block-compounded-victoza XX Bit of an update on compounded terzepatide and semaglutide. The FDA is allowing a grace period of 60 days before starting to enforce the end of allowing compounds of Mounjaro. Meanwhile, semaglutide remains on the FDA's shortage list for several dose strengths, though all doses have been reported as “available” since late October 2024. Compounding pharmacies, especially larger 503B “outsourcing facilities,” maintain they provide an essential public service by offering lower-cost versions of medications that can cost over $1,000 per month. Many insurers still refuse to cover brand-name GLP-1 products for weight loss. Yet  the FDA has reported hundreds of adverse event reports allegedly linked to compounded versions of these drugs, which do not undergo the same rigorous manufacturing inspections and clinical testing as approved brands.   https://www.drugdiscoverytrends.com/compounders-and-drugmakers-clash-over-compounded-weight-loss-drugs-with-fda-in-the-middle/ XX Interesting story here.. this study says a fecal transplant can help people with type 1 and severe gastroenteropathy. The researchers say diabetic gastroenteropathy commonly affects individuals with type 1 diabetes, causing debilitating symptoms like nausea, vomiting, bloating, and diarrhea; however, treatment options remain limited. Researchers conducted a novel clinical trial to test the benefits of FMT in adult patients with type 1 diabetes and severe symptoms of gastroenteropathy, who were randomly assigned to receive either FMT or placebo capsules as the first intervention. After four weeks, Compared with placebo, FMT led to significant changes in the diversity of the gut microbiome. https://www.medscape.com/viewarticle/fmt-shows-early-success-type-1-diabetes-bowel-issues-2025a10000bg XX A couple of weeks ago, listeners told me that the Dexcom geofencing issue we reported on seems to be resolved. Dexcom is now confirming this. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn't reinstall or use the app without customer support. As of last month, the geofencing issue has now been resolved with the latest Dexcom G7 2.6 app update. Can I travel with my Dexcom G7? | Dexcom XX Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead the U.S. market for CGMs, agreed on Dec. 20 to resolve all outstanding patent disputes and not sue each other over patents for 10 years.   Dexcom and Abbott previously reached a settlement in 2014 related to their diabetes devices, which included a cross-licensing deal and an agreement not to sue each other until 2021. After that agreement expired, the companies filed a volley of patent lawsuits. https://www.medtechdive.com/news/abbott-dexcom-settle-cgm-patent-lawsuits/736300/  

During a special episode of The Huddle recorded live at our 2024 annual meeting, we sat down with incoming ADCES President Veronica Brady, PhD, FNP-BC, BC-ADM, CDCES, FADCES. Veronica discussed the impact she wants to leave behind as President this coming year, as well as the concept of unconscious bias, how it shows up in our everyday lives and in working as health care professionals, and how we can practice cultural humility to better serve the needs of people with and at risk for diabetes. Please note: since the recording of this episode, Kirsten Yehl has since moved on from ADCES to pursue another professional opportunity. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Today, we're diving into the intersection of diabetes and the healthcare system with an incredible guest – Natalie Bellini, who brings over 50 years of lived experience with type 1 diabetes and expertise from the forefront of diabetes care. As an Endocrine Nurse Practitioner, Certified Diabetes Care and Education Specialist (CDCES), and Program Director for Diabetes Technology at University Hospitals in Cleveland, Natalie is also the host of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives. Throughout her career, she has been a trailblazer in advancing diabetes care, publishing studies on topics like GLP-1s and groundbreaking diabetes technology, and speaking nationally and globally to advocate for the community. In this episode, we discuss key issues in the doctor-patient relationship and what needs to change, the role of technology in improving outcomes when patients are empowered with education, the challenges many people with type 1 diabetes face, and the critical importance of early screening for type 1.Time Stamps:  (02:58) "Diabetes kind of found me, I didn't find it." (03:30) The Evolution of Natalie's Career (05:57) Being Diagnosed 50+ Years Ago & the Technological Advances Made Since (12:50) How the Education Around T1D and the Complications Have Changed(14:00) Balancing Patient Care with Healthcare System Demands  & The Growing Crisis of T1D Misdiagnosis with Adults. (16:00) Emotional and Psychological Aspects of Diabetes Management(16:41) Barriers to Effective Diabetes Management (19:54) “You should never say you're fine when you walk into an endo's office.”(20:25) Why So Many T1Ds Are Still Struggling (With or Without Technology) (32:00) The Importance of Addressing Emotions in Diabetes Management(34:55) The Truth About AID (40:26) The Importance of Early Detection(41:00) “In the US, they are recommending first-degree relatives be screened and people aren't doing a great job of it because we need to educate the right people.” (42:26) The Science of Understanding Antibodies (52:49) Finding the Support You Deserve What to do now:Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop when new episodes drop.Doors are open for the January 2025 round of our signature group coaching program. Apply for coaching and talk to our team so you can reclaim the life you deserve. Be ready to treat very low blood sugar with Gvoke HypoPen® (glucagon injection). To find out more, go to GvokeGlucagon.com/RiselySee Important Safety Information: https://www.gvokeglucagon.com/#important-safety-informationSee Full Prescribing Information: https://bit.ly/3baHqAODisclaimer: Nothing you hear on the Reclaim your Rise podcast should be a substitute for personalized professional medical advice. Please always consult your physician or other medical professional before making any changes to your diet, insulin dosages, or healthcare plan. 

Recorded live at ADCES24, we sat down with Jane Jeffrie Seley, DNP, MPH, MSN, GNP, BC-ADM, CDCES, CDTC, FADCES​ to talk about the latest in diabetes technology and what to expect in the coming year, how diabetes technology overall is evolving and changing, and how diabetes technology can more seamlessly be integrated into primary care settings.Please note that this episode was recorded in August and some of the technology and updates discussed in future tense may now be in different stages of development or release. References to specific devices and manufacturers are for educational purposes and do not represent an endorsement from ADCES.Links: Register to view ADCES24 on-demand content: ADCES24 (adcesmeeting.org)Find up-to-date diabetes technology product information, device training, professional education and more on danatech: Diabetes technology for healthcare professionals | Danatech (adces.org)Find your technology competency level and resources to dive deeper with our tech competency tool: Technology Competency Finder| Danatech (adces.org)To learn more about the latest and greatest in diabetes technology, register for our Diabetes Technology Conference: Diabetes Technology Conference 2024 (eventscribe.net)To take a deeper dive into the integration of diabetes technology in primary care by checking out this two-part course developed in partnership with the American Association of Nurse Practitioners (Made possible thanks to a grant from Helmsley Charitable Trust).:Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical Scenarios (0.75 CE/CME)Part 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case Studies (1 CE/CME)Learn more about the PANTHER Program: Diabetes Technology. Deciphered. | PANTHER ProgramVisit diatribe: Making Sense of Diabetes | DiaTribeVisit the Medical Professional's Reference website: Prescription & OTC Drug Info | Side Effects, Interactions & Dosages (empr.com)Visit the ADA Consumer Guide: ADA Consumer Guide (diabetes.org)Find resources from DiabetesWise: Home » DiabetesWise Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

In this episode of the "We Are T1D" podcast, Mike and Jack share their weekly adventures, bringing laughs and relatable moments for everyone navigating Type 1 Diabetes. Tune in as they discuss Jack's needle, Mike's TikTok success, and a hilarious run-in with a "Karen" in the diabetes community. Whether it's Jack avoiding a carnival or the duo tackling the highs and lows of blood sugar management, this episode offers humor, insights, and valuable tips on living with T1D. Perfect for anyone in the diabetes community looking for laughter and support! 02:09 - Jack Week & Being lazy 04:00 - Mike's Week & Drama 09:09 - Diabetes Admin & Flying 14:27 - The huge spider 17:02 - Time In Range 35:21 - Listener Wins Join the conversation and share your stories with the T1D community. Don't forget to rate, review, and subscribe to help others find the podcast. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Share your stories at https://wearet1d.com New episodes are released every Sunday & Wednesday PS. If you would like to be a guest on the podcast, please go to the website https://wearet1d.com/guest-booking and fill out the form. Stay tuned for more listener stories and community wins!  

This week on The Huddle, we're resharing an episode with Miguel Johns, Co-Founder & CEO of mmnt and creator of Milton. Miguel discussed how the use of artificial intelligence (AI) can benefit health care professionals across the diabetes space and how this technology is growing and changing. Topics include addressing some of the current opportunities and challenges associated with AI in health care, how AI can provide improved clinical decision support, and where this technology may be headed in the future.Explore danatech here: Diabetes technology for healthcare professionals | Danatech (adces.org)For more information on Miguel or mmnt, visit Milton | Powered by MMNT (getmilton.com)View a recorded annual conference session on AI and more by registering for ADCES24 On Demand: ADCES24: Diabetes Care, Education and Technology (mcievents.com)Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

As we step back into the episode with Ryan Taylor we touch on his time on Geordie Shore to the unexpected challenges and connections he made along the way, Ryan offers a candid look at the highs and lows of living with diabetes in the public eye. Ryan discusses the intricacies of dealing with type 1 diabetes in high-pressure environments, the misconceptions about the condition, and the importance of community support. He also touches on the impact of social media on diabetes awareness and the often overlooked role of vitamins in managing hypo awareness. Listeners will find inspiration in Ryan's journey, as he balances the demands of his career with the realities of diabetes, all while advocating for a more open and positive dialogue around the condition. 01:19 - Geordie Shore Talk 05:51 - Did you have any seriously bad hypos? 13:30 - Whats your favourite hypo treat? 15:01 - Do you weigh or Guesstimate? 21:10 - Diabetics can be negative 23:58 - Only one in my school 24:32 - Three common medications can cause insulin resistance 29:11 - There's so little focus on actual diabetes 29:54 - Did you see diabetes taking you to where you are now? 34:51 - Ryan says talking about diabetes makes him focus on his own diabetes 37:53 - Contact Info Join the conversation and share your stories with the T1D community. Don't forget to rate, review, and subscribe to help others find the podcast. Follow The Podcast https://www.instagram.com/wearet1d Follow Ryan on Instagram https://www.instagram.com/ryancbtaylor Follow Ryan on TikTok https://www.tiktok.com/@ryant1d Share your stories at https://wearet1d.com   New episodes are released every Sunday & Wednesday   PS. If you would like to be a guest on the podcast, please go to the website https://wearet1d.com/guest-booking and fill out the form.  

Consultant360 spoke with Viral Shah MD, Professor of Medicine in the Division of Endocrinology and Metabolism at the Indiana University School of Medicine, and Chair of the ADA Diabetes Technology Interest Group. We spoke with Dr. Shah to discuss new advancements in the field of diabetes technology, what excites him about diabetes technology when looking ahead, and more.

Join Maria A. Mogollon, MSN, APRN, FNP-BC, a Diabetes and Obesity Nurse Practitioner and former Internal Medicine physician in Venezuela, and Jeff Unger, MD, FAAFP, FACE, DACD, Director, Unger Primary Care Concierge Medical Group, renowned Board-Certified Family Physician, Diabetologist, and co-author of the AACE 2021 Clinical Practice Guideline for the Use of Advanced Technology in the Management of Persons with Diabetes Mellitus, as they delve into crucial topics in diabetes technology. Key topics discussed include the benefits and cost-effectiveness of continuous glucose monitors (CGM) compared to traditional finger-stick methods, practical implementation into practice workflows, interpreting CGM data, and identifying ideal candidates for CGM use. Through case studies and practical examples, they address common concerns and barriers to CGM adoption, providing valuable insights for healthcare professionals on how to have effective conversations with patients and integrate CGM technology into patient care.

For those with diabetes who use insulin pump therapy, having access to training and education on this technology is key to success. David Jopke, DNP, FNP-C, BC-ADM, CDCES, Tracy Newell RD LD, CDCES, RD, LD, CDCES, Erin L. DaRosa, MBA, RDN, LD, CDCES join The Huddle to talk about their experiences creating a  team-based formal process for becoming an insulin pump trainer, and how practice settings that want to offer insulin pumps and automated insulin delivery system options to people with diabetes can create their own formalized process.Learn more about HealthPartners here: HealthPartners – Top-Rated insurance and health care in Minnesota and WisconsinView danatech's resources on insulin pumps & AID here: Insulin Pumps l diabetes training and education l Danatech (adces.org)Learn more about the Panther program here: Diabetes Technology. Deciphered. | PANTHER Program Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

We know research is crucial for making continued advances in diabetes care for all populations. Rachel Stahl-Salzman, MS, RD, CDN, CDCES, and Kerri Knippen, PhD, RDN, LD, BC-ADM, FAND, join us on The Huddle to talk about their latest research projects related to pregnancy in diabetes, some of the outcomes and learnings of each study, and how diabetes care and education specialists can be leaders in this work, even without a research background.View Rachel's research poster diving deeper into this topic here: Annual QIPS Symposium | Weill Department of Medicine (cornell.edu)Learn more about Kerri's project here: https://www.eeds.com/enduring_material.aspx?AIN=005243415&SIN=230144&Display_Portal_Nav=true https://bsmh.zoom.us/rec/play/dNYY9PJAVNjh_wJCglFQuYOU9GYRTC4JYP1xEr3eqd5037qGu1kvWbgs0Mw35SdAhBtm-W66tyZCnDv8.FBeiYIeEMAKXck4F?canPlayFromShare=true&from=share_recording_detail&startTime=1713455116000&componentName=rec-play&originRequestUrl=https%3A%2F%2Fbsmh.zoom.us%2Frec%2Fshare%2F6jgesPiUBq5EIbX8P7K0pzRJ4yKEb-HPxmBMMhqUZxbBBqREek8OvlNR7vh3aQR2.hQwbtfqHOQ8tp3uF%3FstartTime%3D1713455116000Join the poster presentations at #ADCES24 to learn even more about Kerri and Rachel's work! Learn more and register for the conference here: ADCES24 (adcesmeeting.org)Learn more about the ADCES Foundation here: ADCES Foundation Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Contact the showProfessor Partha Kar has made sure the technical advances in measuring blood sugar are available to everyone living with Type 1 diabetes in the UK.  Partha had to overcame massive hurdles to make sure the technology was not just available to a privileged few. He discusses with Maggie and Andrew his inspirational leadership style and philosophy that have helped him to move mountains in the NHS.Vote for One in Six Billion in the British Podcast Awards: https://www.britishpodcastawards.com/voting

Kristine Batty, APN, BC-ADM, and CDCES talks about her experience both living with Type 1 diabetes and working with people with diabetes as a CDCES, and how understanding both sides of the desk can help to optimize health outcomes. Visit danatech here: Diabetes technology for healthcare professionals | Danatech (adces.org) View Kristine's video series below:Reducing Diabetes Technology Burnout (youtube.com)Continuous Glucose Monitoring: Managing Expectations (youtube.com)Breaking Down Diabetes Technology Barriers (youtube.com)The Essentials of CGM Accuracy (youtube.com) Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

In this episode of the podcast Rob is solo as he interviews Dr. Anath Shalev, a diabetes researcher turned founder of startup Tiximed. Dr. Shalev discusses the discovery of TixnIP, a protein involved in oxidative stress in beta cells, and its potential for treating diabetes. The conversation covers the development of TIX 100, an oral medication targeting TixnIP, its implications for type 1 and type 2 diabetes, and the differences from existing diabetes treatments like SGLT2 inhibitors and GLP-1 agonists. Topics discussed: * Dr. Anas Shalev's background in diabetes research and founding of Tiximed * Discovery of TixnIP and its role in beta cell health * Potential of TIX 100 as a novel oral medication for diabetes treatment * Comparison of TIX 100 with existing diabetes treatments like SGLT2 inhibitors and GLP-1 agonists * Research process behind TixnIP inhibition and development of TIX 100 * Future of diabetes care, combination therapies, and impact on patients' lives * Information about Tiximed, clinical trials, and ways to support the research 00:18  Revolutionizing Diabetes Treatment: From Researcher to Founder 03:47  Revolutionizing Diabetes Treatment: Targeting Beta Cells and Glucagon Levels 13:47  Revolutionizing Diabetes Treatment: Targeting Beta Cells in Type 1 and Type 2 Diabetes 17:35  Revolutionizing Diabetes Treatment with Ticks 100: A Breakthrough in Addressing the Root Cause of the Disease 27:35  The Limitations and Advantages of Verapamil in Diabetes Care 29:47  Advancements in Diabetes Technology and Research: A Look into the Future 33:04  Exploring Diabetes Treatment Innovations with Dr. Shalev Topics discussed: 1. Mila's Personal Journey including leaving her job to focus on Hangry Woman full-time 2. Career Shift and Health Coaching: Transition from a marketer to a health coach 3. Bridging the gap between fear of eating and enjoying meals 4. Importance of Self-Care and Boundaries: Prioritizing self-care to avoid burnout 5. Support System in Content Creation: Managing overwhelm by acknowledging limitations 6. The role of support team members in providing feedback and managing projects 7. Navigating Changes in Diabetes Diagnosis: Transition from type 2 to type 1 diabetes diagnosis 8. Representing Diverse Voices in the Diabetes Community: Importance of diversity representation and transparency in collaborations 9. Kindness, Respect, and Accountability: Impact of chronic illness on behavior and comparison culture 10. Addressing misconceptions about online personas and supporting creators 11. Building a Supportive Diabetes App Key takeaways: * Embracing personal growth amidst challenges and life changes * Prioritizing self-care, setting boundaries, and recognizing emotional well-being * Navigating career shifts and advocating for representation in the diabetes community * Building a supportive community and offering personalized health support through technology * Upholding kindness, respect, and accountability in online interactions and content creation References: * The Hangry Woman * Glucose Guide App 00:00  Celebrating Diabetes Stories Worldwide 00:02  The Evolution of Mila Clarke: Navigating Life Changes and Diabetes Management 04:15  From Marketer to Health Coach: A Journey of Personal and Professional Growth 08:16  Learning to Set Boundaries and Prioritize Self-Care: A Journey of Self-Discovery and Growth 12:16  Navigating Burnout and Building a Support System in Content Creation 17:26  Navigating a Diabetes Diagnosis Change: Impact on Community, Relationships, and Advocacy 23:49  Navigating a New Diagnosis and its Impact on Personal Branding 28:04  Breaking Barriers and Building Bridges in the Diabetes Community 32:36  Debunking Myths and Realities of Being a Successful Black Woman Entrepreneur 42:36  Embracing Kindness and Abundance in a World of Competition 52:36  Navigating Social Media Etiquette and Misconceptions as a Creator 55:53  Navigating Online Criticism and Embracing the Journey to Success in Content Creation 01:02:49  Revolutionizing Diabetes Support with a Unique Pocket Guide App 01:06:10  Empowering Diabetes Management through Personalized Support and Community Connection 01:09:21  Building a Supportive Community Beyond Social Media Platforms 01:14:05  Empowering Health and Support Through a Unique Approach 01:17:12  The Value of Ads and Support in Providing Free Content and Services

Jack kicks things off with his win of the week – celebrating his fifth wedding anniversary with a weekend full of food, drinks, and live music at Pub in the Park. From enjoying performances by Boyzlife and DJ sets by Vernon Kay and Kimberly Wyatt, to indulging in free samples of gin, ale, and snacks, it's a festival experience worth recommending. Mike shares his win of achieving 83% in-range blood sugars for the week, attributing his success to consistent gym sessions and the MyFitnessPal app. The hosts discuss the importance of tracking macros and the benefits of using such apps for managing diabetes. However, not everything is smooth sailing. Jack recounts a frustrating hospital appointment where he felt unfairly criticised for running his blood sugars "too tight." Despite achieving 93% in-range, his nurse focused on the 2% lows, leading to a heated exchange. This discussion highlights the importance of constructive feedback and understanding the lived experience of diabetes. Mike's struggle this week revolves around resisting the temptation of share bags of crisps and popcorn, while Jack introduces a new hypo treat – honey roasted cashews with cinnamon, discovered at the festival. The episode wraps up with the 'Listener Wins' segment, celebrating the community's triumphs, from improved in-range percentages to smashing gym sessions and even winning at crazy golf. Whether you're looking for motivation, a good laugh, or just a sense of connection, this episode has it all. Remember, you're not alone in this – WE ARE T1D! Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Get your wins on the podcast at https://wearet1d.com New episodes go out every Sunday & Bonus On A Wednesday! Don't forget to Subscribe/Follow, Rate, and Review to help others find the podcast and join the T1D community.    

Warning: This episode is not for the faint of heart or those easily offended. It's raw, it's real, and it's a bit naughty. You've been warned. Brace yourselves for the long-awaited and unabashed Part Two of the Jonsel episode on 'We Are T1D' - the podcast that doesn't just talk diabetes, it lives it. Hosts Mike and Jack, the candid voices of Type 1 Diabetes, delve into the gritty, unpolished side of living with T1D, with their guest who's as real as it gets. Jonsel, a man who's not afraid to speak his truth, shares his journey through the entertainment industry, his battle with the highs and lows of diabetes, and the stark reality of managing this chronic condition in the public eye. From the heartache of empty theatres to the frustration with charities, Jonsel's story is a rollercoaster of emotions and experiences that many with T1D can relate to. Get ready for some outrageous hypo tales that will have you in stitches, discussions on the taboo topic of diabetes and sex, and the kind of uproarious banter that only comes from three guys who know how to laugh in the face of adversity And for those who've been touched by Jon's candidness, his books, 'Diabetes Won't Defeat Us' and 'Keep Calm I'm Only Diabetic', are available on Amazon. Plus, don't miss his powerful short film, 'Hypo', on YouTube - a must-watch that sheds light on the silent struggles of living with T1D. Follow Jonsel on Instagram @jonsel99 and join the conversation that's breaking barriers and building bridges in the T1D community. Remember to Subscribe/Follow, Rate, and Review to support the podcast and help spread the word about the real life of living with Type 1 Diabetes. Share your stories, find your tribe, and never forget - you're not alone on this ride. Until next time, keep it real, keep it raw, and keep laughing through the lows. Peace out, and stay syringed! Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Get your wins on the podcast at https://wearet1d.com  

This week, they're joined by the multi-talented Jonsel, whose journey with Type 1 Diabetes is as diverse as his career spanning from music to professional football, and even to the silver screen. Jonsels candid storytelling transports us from his mother's Type 1 diagnosis to his own, revealing the stark reality of diabetes awareness—or the lack thereof—in the '90s. He shares the heart-wrenching account of how his budding football career in Turkey was cut short by a misunderstanding of his condition, underscoring the importance of diabetes education and advocacy. With humor and raw honesty, Jonsel tackles the challenges of Type 1 Diabetes head-on, from dealing with hypos to confronting the misconceptions that surround the condition. His unapologetic attitude and refusal to play the victim card make for an episode that's as enlightening as it is entertaining. Be prepared for laughter, tears, and everything in between as Jonsel lays it all out, reminding us that while Type 1 Diabetes might shape our lives, it doesn't have to define them. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Follow Jonsel https://www.instagram.com/jonselg99 Get your wins on the podcast at https://wearet1d.com New episodes go out every Sunday! Don't forget to Subscribe/Follow, Rate, and Review to help others find the podcast and join the T1D community.  

Living with Type 1 Diabetes (T1D) is a full-time job that doesn't come with a manual. But what if you had two friends who could guide you through the highs and lows? Enter Mike and Jack, hosts of the 'We Are T1D' podcast. Mike was diagnosed with T1D at the tender age of ten, while Jack's life changed at 30. Together, they form a duo that offers an unfiltered look into the life with this chronic condition. Their podcast is not just a series of discussions; it's a lifeline for those who may feel isolated in their struggles. Listening to Mike and Jack feels like catching up with old friends who understand exactly what you're going through. They don't shy away from the tough topics, but they also remind you that there's always a silver lining. As Mike puts it, "dark clouds always disappear." If you or someone you know is navigating the complex world of Type 1 Diabetes, tune in to the 'We Are T1D' podcast. Mike and Jack are here to remind you that while the journey may be challenging, there's a community ready to walk with you every step of the way. Listen to their stories, share in their wisdom, and join a conversation that's changing lives, one episode at a time. Don't forget to follow them on social media for more insights and to become part of the 'We Are T1D' family. Because as they say, no one should have to face diabetes alone. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Get your wins on the podcast at https://wearet1d.com New episodes go out every Sunday! Subscribe/Follow, Rate, and Review to help others find the podcast and join the T1D community.  

This is We Are T1D.  Join your hosts, Mike and Jack, as they peel back the curtain on the raw and real-life experiences of living with Type 1 Diabetes. Diagnosed at ages ten and thirty, respectively, these two mates bring a wealth of personal stories and insights to the table, offering a unique look into the day-to-day journey with this chronic condition. As they navigate the complexities of adulthood with T1D, they remind listeners that although they strive to keep it clean, life—and language—can get a bit messy sometimes. Their honest and open dialogue serves as a beacon for those in the T1D community, reinforcing the message that no one should ever feel isolated in their battle with diabetes. Take their words as a companion on your own T1D journey, but remember, while Mike and Jack are seasoned veterans in the T1D world, they're not medical professionals. Their shared experiences are meant to guide, inspire, and unite, not to substitute for professional medical advice. So, buckle up for a ride filled with authenticity, humor, and the kind of camaraderie that only comes from two friends who truly understand the highs and lows of life with Type 1 Diabetes. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Dive into the community at https://wearet1d.com Remember to Subscribe/Follow, Rate, and Review and stay in the loop with the latest episodes. Stay genuine, stay connected, and let's embrace the unfiltered reality of living with T1D.

Jack revels in a rare lazy Sunday, achieving the elusive 'all day in range' victory while feasting to his heart's content. Meanwhile, Mike shares a harrowing night battling ketones and the importance of putting health first, reminding us that sometimes, calling in sick is the only option. The pair delve into the perplexities of diabetes and driving, discussing an official document that offers a fresh perspective on the '5 to drive' rule. Jack's discovery prompts a deep dive into the DVLA guidelines, sparking conversation and a call for listener opinions. From hypo symptoms that sneak up while binging your favorite show, to the stealthy lows that ambush you post-bolus, Mike and Jack share their personal experiences and the lessons learned along the way. They also touch on the benefits of reducing carb intake and the impact of hydration on blood sugar control. As they venture into the realm of food, Jack teases with tales of culinary exploration, setting the stage for a segment on new recipes and the joy of shared cooking experiences. And let's not forget the listener wins, celebrating everything from improved A1C levels to mastering McDonald's without a glucose spike.   Join Mike and Jack as they laugh, commiserate, and navigate the rollercoaster that is Type 1 Diabetes. Their camaraderie is infectious, their insights invaluable, and their spirit unbreakable. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Join the conversation at https://wearet1d.com   Remember to Subscribe/Follow, Rate, and Review to keep up with the latest episodes and to be part of our supportive T1D community. Share your triumphs, join the banter, and let's tackle the highs and lows of T1D together.   Stay inspired, stay connected, and let's continue to take control of our T1D journey.

Join us as we talk about our experience at the 18th Annual Diabetes Technology Meeting in Europe (ATTD 2024). In this podcast, we'll be unpacking our favorite lectures from the event, which hold some very exciting data and insights. From cutting-edge advancements in diabetes technology to the latest developments in medications, we'll cover it all. Tune in as we explore the forefront of diabetes innovation and share our experiences from this meeting!In this episode, we will talk about:What updates are happening in diabetes technology? What are updates in diabetes medications? What is new with CGMs and Type 2 Diabetes? What is the silence all alert on your Dexcom G7? What is a continuous ketone meter and when is it coming? What is the most common cause of DKA in type 1's? What is time in tight range? What is Tzield (data information)? What is the new data on Afrezza? What is new information about SGLT2 inhibitors? What data information came out regarding Mounjaro? Show notes:Diabetes Technology Podcast - https://tcoydthepodcast.transistor.fm/47TCOYD Video Vault - https://tcoyd.org/tcoyd-video-vault/TCOYD Live PLUS Diabetes Technology https://tcoyd.org/live-feb-2024/?  ★ Support this podcast ★

In this heartwarming episode of We Are T1D, Mike and Jack sit down with Maria, a familiar voice from the community who always engages with the podcast's wins and struggles. Maria, a healthcare assistant and a Type 1 diabetic, shares her story of diagnosis, which includes a surprising revelation of fruity breath leading to a DKA diagnosis, and the steep learning curve of managing insulin injections. As they delve into the intricacies of shift work with T1D, Maria reflects on the challenges and strategies she employs to keep her blood sugars in check amidst the unpredictable routine. The conversation takes a humorous turn with tales of injection mishaps, including the perils of biting off needle caps and more! Listeners are invited to join the banter as the trio discusses the pros and cons of different CGM sensors, the struggle to keep them adhered during sweaty gym sessions, and the surprising shortage of alcohol swabs that once accompanied the sensors. Maria also shares her approach to carb counting (or the lack thereof), the importance of considering future activities when dosing insulin, and the therapeutic effect of a well-timed hypo snack. The episode culminates with Maria's sage advice for those newly diagnosed with T1D, emphasizing the strength of the online community and the wealth of resources available. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Connect with Maria https://www.instagram.com/t1d_maria_greenwood Join the conversation at https://wearet1d.com Don't forget to Subscribe/Follow, Rate, and Review to be part of our vibrant T1D family. Share your stories, laugh along with ours, and let's navigate the ups and downs of T1D together. Stay strong, stay informed, and keep sharing those hypo stories with a side of ketchup (weighed or not)!

Diabetes technology is getting better and better. We have automated insulin systems that link pumps and CGMs, and smart insulin pens that have precise calculations and reminders. It's been quite the evolution over the past few years! But outcomes – time in range, A1Cs, aren't exactly where experts thought they might be. I'm talking to Dr. Stephen Ponder about why that is, how a social media post he shared about this caused a strong reaction, and what does work for better long term outcomes. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com    

In this special anniversary episode, Mike and Jack celebrate a year of living loud with T1D. They're not just marking the occasion with a cake (which they may or may not weigh), they're also inviting you to join in the festivities and reflect on a year of shared experiences, wins, and the occasional struggle. The duo kicks off with their signature humor, debating the merits of weighing ketchup and the perils of dual phone usage due to CGM sensors. Jack recounts his Italian restaurant adventure and his daring attempt at carb guesstimation, while Mike vents about the treachery of brioche bread and its impact on blood sugar levels. Amidst the laughs, they delve into the serious side of T1D management, discussing the benefits of a new app, Gluroo, which helps log diabetes data and fosters community support. They celebrate listener wins, from steady glucose levels during illness to managing sugars during massage therapy, and even a cat bringing home an unconventional gift. The episode wraps with a heartfelt thank you to the global T1D community, acknowledging listeners from all corners of the world for their support and shared journey. Mike and Jack emphasize the importance of laughter, human connection, and the determination to live well with T1D. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Dive into the T1D community at https://wearet1d.com   Don't forget to Subscribe/Follow, Rate, and Review to be part of our growing T1D family. Share your stories, embrace the laughs, and let's continue this journey together. Here's to another year of thriving with T1D!   Stay joyful, stay connected, and let's keep bouncing through life with T1D.

Mike and Jack bring the real talk and real laughs, diving into the world of Type 1 Diabetes with their usual London charm. They remind us that they're not doctors, just two ordinary blokes sharing their T1D journey to ensure no one feels alone.  The duo doesn't shy away from the serious stuff. They discuss the 25 rule for protein and fats, a game-changer for blood sugar management. Jack scores a win with an unexpected extra sensor from Libra, while Mike learns a valuable lesson about split bolusing. The episode is sprinkled with personal victories, from Zoe's night-time hypo handling to Amber's creative low alarm wake-up calls. And don't miss the new food segment, where the guys share their "demon foods" of the week — kebabs and homemade parmesan chicken that pack a punch. Listeners chime in with their wins, from improved time in range to starting T1D groups in their cities. It's all about community, encouragement, and a few laughs along the way. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Get involved at https://wearet1d.com Catch the latest T1D tales and tips, and remember to Subscribe/Follow, Rate, and Review to stay part of the conversation. Grab life by the balls, pluck those metaphorical pubes, and join us next week for another episode that's as enlightening as it is entertaining. Stay connected, stay inspired, and keep laughing through the T1D journey.

Evaluating Diabetes Technology: The Pros & Cons of Different Devices – Featuring David Ahn, MD Endocrinologist; Chief of Diabetes Services, HoagTAKING CONTROL OF YOUR DIABETES® - THE PODCAST! ...With Expert Endocrinologists Living with T1D, Drs. Steven V. Edelman & Jeremy PettusIn this episode, we talk about the most popular CGM and insulin delivery systems that have changed the diabetes world. Our special guest David Ahn, MD, Endocrinologist and chief of Diabetes Services, Hoag shares his insights on diabetes technology and it's future.In this episode, we will talk about:Who is David Ahn?The importance of CGM technology in the modern worldCGMs covered in this episode: Dexcom G7, Libre 2, Libre 2 PLUS and Libre 3, EversenseHybrid closed-loop systems overview & insulin delivery systems (AID): Tandem & Mobi from Control IQ, Omnipod 5, Medtronic 780G, iLet Bionic PancreasHow CGMs influence a basal insulin rateAn “algorithm” as a brain of CGMSteve's experience with Medtronic 780GFollow our guest David Ahn on Instagram: https://www.instagram.com/ahncall/Connect with Our Supporting Diabetes Companies:Dexcom: https://shorturl.at/wzARXMedtronic: https://shorturl.at/orwB8**Tune in for 2 new episodes each month! Like what you hear and want to help us grow? Please rate and review this podcast so we can reach more people living with diabetes!** ★ Support this podcast ★

In this episode of We Are T1D: Type 1 Diabetes, hosts Mike and Jack are back with their signature blend of humor and honesty, tackling everything from the triumphs of diabetes management to the tribulations of tech troubles. Mike kicks off with a heartwarming win of taking back control, boasting disciplined hypo treatment and an active lifestyle that's got his blood sugars in check. Jack, on the other hand, celebrates a victory with the pharmacy that's worthy of applause. The duo doesn't stop at the wins; they dive into the struggles too. Mike opens up about an offensive email from a weight loss agency that fails to distinguish between Type 1 and Type 2 diabetes, prompting him to deliver a much-needed education on the differences. Meanwhile, Jack shares his frustration with a sensor that's been acting up, suspecting that humidity and wet conditions might be the culprits - a discovery that could be a game-changer for fellow T1Ds.   The conversation takes a serious turn as they discuss Diabetes UK's controversial partnership with Slimming World, questioning the organization's focus and priorities. But it's not all heavy; the laughs are plentiful, especially when they consider the absurdity of a planet named George and the legality of swearing in front of a corpse in Texas.   As they wrap up, the hosts reflect on their HbA1c averages, with Mike taking a narrow victory over Jack. They invite listeners to suggest future podcast guests, emphasizing that this show is for the community, by the community.   - Follow The Podcast https://www.instagram.com/wearet1d - Follow Mike https://www.instagram.com/t1d_mike - Follow Jack https://www.instagram.com/t1d_jack - Share your thoughts and guest suggestions at https://wearet1d.com   Tune in for an episode that's as informative as it is entertaining, and remember to Subscribe/Follow, Rate, and Review to stay connected with the T1D family.